Eurofins Discovery

How do you comprehensively characterize therapeutic antibodies? Don’t miss out on this case study demonstrating our molecular approach to thoroughly characterize trastuzumab, a humanized monoclonal antibody targeted against the ErbB2 protein and approved to treat HER2-positive breast cancer. This case study highlights guidelines from regulatory agencies regarding monoclonal antibodies. It shows how the Eurofins Discovery approach provides you with the robust, reliable, and quality data you need to make confident decisions that will progress your program into preclinical development. Download now to see how Eurofins Discovery’s safety screening and profiling vigilance can save you time and resources in your biotherapeutics program. Get more details: https://lnkd.in/gnNk_7VQ #biotherapeutics #trastuzumab #drugdiscovery #eurofinsdiscovery

🚨 Join Eurofins Discovery at AusBiotech 2024! 🚨 We’re excited to invite you to AusBiotech 2024, taking place October 30th - November 1st in Melbourne. Don't miss the opportunity to hear from Alastair King, Ph.D., Head of Biology at Eurofins Discovery, as he participates in a panel discussion on "Translational Biology Platforms as Animal Model Alternatives." 📍 Visit us at Booth #25: 🔬 Our Integrated Drug Discovery Services offer instant access to 700+ discovery scientists empowered by state-of-the-art technologies coupled to Chemistry expertise and the industry's largest portfolio of 12,000+ validated assays. We provide your team with dedicated support, target class expertise, care of your intellectual property, and therapeutic focus so you can deliver candidates with the best chance to be first, or best, in class. 🤖 We offer AI solutions that complement our ADME services and virtual screening to make your hit finding program even more efficient. 🤝 Explore potential collaboration opportunities with our experts.  We look forward to seeing you there! Feel free to reach out if you're attending or would like more information. #AusBiotech2024 #DrugDiscovery #TranslationalBiology #LifeSciences #Eurofins #DiscoveryAI

🚀 Supercharge Your Drug Discovery with EMERALD Machine Learning-Powered Discovery! Ready to accelerate your drug discovery process? Introducing EMERALD, our cutting-edge machine learning-powered discovery system, designed to revolutionize how you leverage data in your research. What is EMERALD? EMERALD (Exclusive Machine Learning Resource Leveraging Data as a Service) provides a comprehensive dataset of validated assays, drugs, drug failures, and pharmacological tools. This robust, rich dataset is perfect for jump-starting your AI modeling and supercharging your discovery efforts. 🔗 Discover More: Learn how EMERALD can transform your drug discovery efforts and take advantage of our cutting-edge datasets. https://lnkd.in/gWSBpEi4 Ready to elevate your drug discovery game? Dive into the power of EMERALD and make informed decisions with confidence! #DrugDiscovery #MachineLearning #AI #Innovation #DataDrivenDiscovery

To better serve our customers, we are moving to a larger, modernized facility that will accommodate our expanding operations and growing business. Beginning November 11, our Fremont (Albrae St.) laboratories, manufacturing facility, & offices will move to a new location. NEW ADDRESS: 47100 Bayside Pkwy Fremont, CA 94538 USA   All correspondence, shipments and in-person visits will take place at our new location beginning November 11.   Please email DiscoverXCustomerServices@discovery.eurofinsus.com with any questions. #EurofinsDiscovery #EurofinsDiscoverX #DrugDiscovery

Fight Cancer with Precision Medicines: Antibody Drug Conjugate (ADC) delivery of a cytotoxic drug allows greater specificity than use of the drug alone. This therapeutic modality targets cancer cells while reducing the potential impact on normal cells to improve efficacy and safety. Eurofins Discovery’s OncoPanel® and BioMAP® platforms can aid new ADC therapeutic development! OncoPanel ✔ Supports lead optimization with routine screening using any of our 300+ human tumor cell lines. ✔ Enables the identification of sensitive and resistant tumor types, along with related predictive genomic biomarkers. BioMAP ✔ Generates an actionable phenotypic fingerprint using the Diversity PLUS panel of 12 biological models with 148 clinically relevant protein biomarker readouts. ✔ Enables the identification of broader biological effects and potential toxicity signatures to help de-risk programs by comparison with 4,500+ therapeutic and reference agent profiles. Our experts can help you accelerate & de-risk your ADC program. Contact us today. https://lnkd.in/gDh2fzBP #DrugDiscovery #ADC #EurofinsDiscovery

Unlocking Drug Discovery: New Transport Models Transporters play a crucial role in the movement of ions and molecules across membranes, affecting how drugs and toxins interact in the body. Understanding these interactions is essential, as they can lead to significant clinical drug interactions. As regulatory guidance becomes more harmonized, the demand for robust in vitro models to assess drug transporter engagement grows. Eurofins Discovery is excited to announce our expanded portfolio of transporter models, featuring newly launched cell-based systems for key efflux transporters, P-gp and BCRP. Our innovative offerings include: - P-gp & BCRP knock-out and knock-in MDCKII cell lines created using CRISPR-CAS9 technology. - Low background efflux activity with consistent human transporter expression. - Physiologically relevant models for assessing the uptake and efflux of P-gp & BCRP substrates. Discover how our advanced models can enhance your research. https://lnkd.in/gpTBfPdy #DrugDiscovery #EurofinsDiscovery

🌟 Celebrating Customer Service Week at Eurofins Discovery in St. Charles! At Eurofins Discovery, serving our clients is at the heart of everything we do. Every day, our dedicated Customer Service and Study Director teams work hand in hand with our customers, driving innovation in drug discovery to tackle global health challenges. Customer Service Week was the perfect opportunity to express our gratitude. A huge thank you to our incredible team for their unwavering commitment and expertise, and to our valued clients for their trust and partnership. Together, we’re making a real impact in the world of drug discovery. Need assistance with your drug discovery outsourcing? Please contact us! https://lnkd.in/g3W8Tfec

As your partner in #biotherapeutics, Eurofins Discovery can deliver differentiated platforms and experienced scientific experts who can accelerate assay development, screening cascades, and drug candidate validation for your biologic program. Access our experts for your programs: ·        Target Validation and Antigen Generation ·        Antibody Discovery ·        Antibody Characterization and Optimization ·        Protein Production ·        Gene & Cell Therapy Discovery Get all the details: https://lnkd.in/dQ6tdZ7Y

One day to go! Attend our webinar, "Unprecedented Fragment-Based Screening Using Spectral Shift for GPCRs" on October 17th! Join our experts, Vanessa Porkolab, Maud Sigoillot, and Alexis Moreno, as they reveal cutting-edge strategies for handling challenging recombinant proteins like GPCRs and the crucial role of biophysics in hit discovery and validation. Key Learning Points: ‣ Explore innovative hit-finding strategies for a wide range of targets, including GPCRs. ‣ Understand the importance of high-quality recombinant proteins in fragment screening. ‣ Increase your hit rate and identify novel starting points with our comprehensive fragment library. ‣ Utilize advanced equipment for effective screening cascades and binding confirmations. ‣ Discover how Spectral Shift, Echo® acoustic droplet ejection, and NanoDSF enhance fragment-based screening, providing robust data and high-affinity hit identification. Don’t miss out on this chance to learn from the experts and discover how to advance your research with our innovative technologies. Register now: https://lnkd.in/gFN6CDKA   #Eurofins #DrugDiscovery #Biophysics #MembraneProteins #GPCR

Custom AI Solutions: We're excited to share how Eurofins DiscoveryAI™ is revolutionizing drug discovery. Our dedicated team works closely with clients to create and implement custom AI solutions that enhance lead optimization projects. By merging advanced machine learning techniques with traditional computational chemistry, we ensure each project leverages the latest technology tailored to your specific needs. Our proprietary, high-quality data fuels AI models, delivering accurate predictions and streamlining the identification of potential drug candidates. Collaboration is key! We adapt our solutions to your evolving goals, driving more innovative and successful outcomes in drug discovery. Ready to explore how we can elevate your research? Let’s connect! https://lnkd.in/gRscfq_x #AI #EurofinsDiscovery #DrugDiscovery